• Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

  • Jul 16 2024
  • Duración: 14 m
  • Podcast

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML Por arte de portada

Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.

    Read the full article:
    https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Más Menos
activate_primeday_promo_in_buybox_DT
Enfermedades Físicas Hygiene & Healthy Living Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles